Innovator IBD Breakout Opportunities ETF Rating $42.89 -0.64 (-1.47%) As of 09/23/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatings Innovator IBD Breakout Opportunities ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BOUT Aggregate RatingModerate Buy 2.73Holdings in BOUT have an aggregate rating of Moderate Buy based on 295 analyst ratings issued in the past year covering 22 companies (91.9% of the portfolio).BOUT Aggregate Price Target$42.89High Prediction$42.89Average Prediction$42.89Low Prediction$42.89Holdings in BOUT have an aggregate price target of $42.89 and a range of $42.89 to $42.89 covering 22 companies (91.9% of the portfolio).BOUT Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy3 Buy rating(s)Moderate Buy16 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Innovator IBD Breakout Opportunities ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 22 BOUT Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings7.23%HNGEHinge Health$92.27-2.0%Moderate Buy$103.71 12.4%183.5493 of 5 starsAnalyst ForecastInsider Trade7.07%TGTXTG Therapeutics$56.00-3.6%Hold$63.00 12.5%93.4009 of 5 starsAnalyst Upgrade7.07%TVTXTravere Therapeutics$59.83-0.7%Moderate Buy$68.10 13.8%121.9125 of 5 starsAnalyst Forecast6.96%ELVNEnliven Therapeutics$46.09-4.4%Moderate Buy$75.00 62.7%92.2634 of 5 starsInsider Trade6.93%TXTernium$55.95-0.9%Moderate Buy$54.50 -2.6%114.9311 of 5 stars6.26%NESRNational Energy Services Reunited$32.81-0.8%Buy$33.86 3.2%94.0436 of 5 stars5.92%EMREmerson Electric$154.43+0.2%Moderate Buy$167.83 8.7%244.2856 of 5 stars5.86%EMBJEmbraer-Empresa Brasileira de Aeronautica$75.58-1.8%Moderate Buy$85.00 12.5%54.2324 of 5 starsAnalyst RevisionGap Down5.85%BACBank of America$56.01-0.3%Moderate Buy$64.08 14.4%274.9216 of 5 starsTrending NewsAnalyst Revision4.03%BNYBank of New York Mellon$149.38-0.5%Moderate Buy$157.13 5.2%174.3881 of 5 stars4.02%NTRANatera$390.790.0%Moderate Buy$330.83 -15.3%231.5926 of 5 starsTrending News4.02%PJTPJT Partners$149.51-0.5%Hold$177.50 18.7%74.2227 of 5 starsPositive News3.98%MCOMoody's$474.03+1.0%Moderate Buy$553.61 16.8%204.4953 of 5 stars3.97%KNSAKiniksa Pharmaceuticals International$76.08-2.5%Moderate Buy$87.38 14.8%104.1883 of 5 starsPositive News1.98%CHEFChefs' Warehouse$108.89+0.5%Buy$115.67 6.2%73.1529 of 5 stars1.97%SCCOSouthern Copper$202.14-1.9%Reduce$146.84 -27.4%152.2027 of 5 starsGap Down1.95%NWGNatWest Group$17.93-3.5%Moderate Buy83.4415 of 5 starsGap Down1.95%ONCBeOne Medicines$365.00-0.8%Buy$402.71 10.3%172.7514 of 5 starsPositive NewsAnalyst UpgradeGap Up1.93%GRMNGarmin$287.82+1.1%Moderate Buy$310.17 7.8%84.677 of 5 stars0.99%NEMNewmont$123.57-2.9%Moderate Buy$133.07 7.7%244.5583 of 5 starsTrending NewsGap Down0.97%ETONEton Pharmaceuticals$55.61-2.6%Moderate Buy$67.50 21.4%64.4055 of 5 starsPositive NewsAnalyst Upgrade0.96%ENVAEnova International$167.98-0.6%Moderate Buy$231.67 37.9%94.6487 of 5 starsInsider TradeGap Down This page (NYSEARCA:BOUT) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovator IBD Breakout Opportunities ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovator IBD Breakout Opportunities ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BOUT Stock Alerts